{"product_id":"amyris-bcg-matrix","title":"Amyris Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix - Strategic Snapshot for Amyris\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis BCG Matrix snapshot maps Amyris's bio-based product portfolio across market growth and relative market share, identifying potential Stars in specialty ingredients, Cash Cows among established fermentation-derived lines, and Question Marks in emerging consumer segments. It outlines strategic positioning and resource implications but omits detailed quadrant metrics. Purchase the full BCG Matrix for a quadrant-by-quadrant analysis, data-driven recommendations, and ready-to-use Word and Excel deliverables to inform investment and portfolio decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eB2B Squalane Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris remains the dominant global producer of high-purity, plant-based squalane via its proprietary fermentation, supplying roughly 60-70% of certified clean-beauty squalane volume in 2024 and generating an estimated $95-110M in squalane revenue that year.\u003c\/p\u003e\n\u003cp\u003eAs the beauty industry phases out shark- and olive-derived squalane, plant-based squalane captured ~35% CAGR demand growth 2020-24 in premium skincare, lifting Amyris into a Stars position in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eThe company's scale-up capacity-planned 2025 output of ~3,500-4,000 tonnes\/year-while holding \u0026gt;99% purity keeps Amyris a preferred supplier to LVMH, Estée Lauder and others through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemisqualane for Sustainable Haircare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHemisqualane, a bio-derived alternative to cyclic silicones, is driving high growth in Amyris's haircare lineup as formulators favor its light feel and biodegradability; global demand for silicone substitutes rose 28% in 2024, per Kline, boosting Amyris's market share. \u003c\/p\u003e\n\u003cp\u003eRegulatory pressure-EU restrictions on D4\/D5 since 2023 and pending US scrutiny-positions Amyris to capture displaced volume; company guidance expects hemisqualane to contribute meaningfully to 2025 revenue. \u003c\/p\u003e\n\u003cp\u003eAdoption needs targeted marketing and formulator education; still, pilot sales grew ~150% YoY in 2024, implying hemisqualane could be a primary revenue driver by end-2025 if ramp continues. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCustom Strain Engineering Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe core synthetic-biology platform lets Amyris engineer yeast strains for third-party clients, generating $85M in FY2024 services revenue and growing ~28% year-over-year as pharma and chemical firms de-risk supply chains via biotech. This service model sits in the BCG matrix as a Star-high market growth and strong share-driven by 40+ commercial partnerships and a 15% gross margin premium over product sales. By using AI-guided design and 24\/7 lab automation, Amyris reduces strain development time to 6-9 months, keeping a competitive edge in a bio-economy projected to reach $1.7T by 2030.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainable Fragrance Molecules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThrough multi-year partnerships with Givaudan and Firmenich, Amyris has launched bio-identical fragrance molecules yielding gross margins ~35-40% vs 20-25% for many botanicals in 2024.\u003c\/p\u003e\n\u003cp\u003eThese ingredients deliver price stability-\u0026lt;10% annual price volatility vs 30-50% for natural extracts-and carry verified sustainability credentials (ISCC\/RSPO-equivalent traceability) that luxury brands demand.\u003c\/p\u003e\n\u003cp\u003eWith luxury fragrance market CAGR ~6.5% to 2028 and premiumization, these molecules sit as Stars in Amyris's BCG matrix, driving revenue growth and wallet-share gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh gross margins: 35-40% (2024)\u003c\/li\u003e\n\u003cli\u003eLower price volatility: \u0026lt;10% vs 30-50%\u003c\/li\u003e\n\u003cli\u003eLuxury fragrance CAGR: ~6.5% to 2028\u003c\/li\u003e\n\u003cli\u003ePartnerships: Givaudan, Firmenich\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-based Preservatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmyriss Bio-based Preservatives target the rising clean-label trend, offering bio-fermented molecules that inhibit microbes without parabens or phenoxyethanol; the global natural preservatives market was ~$1.2B in 2024 and is forecast to grow ~9% CAGR to 2030, signaling strong demand.\u003c\/p\u003e\n\u003cp\u003eThe unit is cash-consuming for scale-Amyris reported R\u0026amp;D and scale-up spend of ~$65M in 2024-but shows star traits with high market-share potential in food and cosmetics where premium natural claims command 10-30% price premiums.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size ~$1.2B (2024); ~9% CAGR to 2030\u003c\/li\u003e\n\u003cli\u003eAmyris R\u0026amp;D\/scale spend ~$65M (2024)\u003c\/li\u003e\n\u003cli\u003ePrice premium 10-30% for clean-label\u003c\/li\u003e\n\u003cli\u003eReplaces parabens\/phenoxyethanol; lower safety concerns\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris Leads Squalane Market; Hemisqualane \u0026amp; Services Drive Rapid Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris's Stars: squalane (60-70% market share; $95-110M revenue 2024), hemisqualane (pilot sales +150% YoY 2024; expected 2025 revenue contributor), biotech services ($85M 2024; +28% YoY), fragrance molecules (35-40% gross margin 2024; luxury CAGR ~6.5% to 2028); scale capex ~$65M R\u0026amp;D\/scale 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSqualane\u003c\/td\u003e\n\u003ctd\u003e$95-110M; 60-70% share\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemisqualane\u003c\/td\u003e\n\u003ctd\u003ePilot +150% YoY\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eServices\u003c\/td\u003e\n\u003ctd\u003e$85M\u003c\/td\u003e\n\u003ctd\u003e+28% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Amyris products with strategic actions for Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Amyris BCG Matrix placing each business unit in a quadrant for quick strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFarnesene Industrial Intermediates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFarnesene industrial intermediates remain Amyriss cash cow, supplying 2024 revenue of about $140 million and steady gross margins near 35% that fund operations.\u003c\/p\u003e\n\u003cp\u003eThe production tech is mature-fermentation yields improved to ~0.9 g\/L·h by 2024, cutting unit costs roughly 20% versus 2018 and improving cash conversion.\u003c\/p\u003e\n\u003cp\u003eThose cash flows provided liquidity for R\u0026amp;D, supporting $75 million in 2024 innovation spend and underwriting higher-risk projects across the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Flavor Ingredients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris's Legacy Flavor Ingredients, including bio-fermented vanillin and citrus oils, sit in the Cash Cows quadrant-mature markets with steady global demand (~$4.5B flavors market 2024) and high regulatory barriers that limit new entrants. \u003c\/p\u003e\n\u003cp\u003eWith production capex largely depreciated and 2024 gross margins for specialty ingredients near 60%, these lines generate strong free cash flow and require minimal reinvestment, supporting companywide R\u0026amp;D and growth projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVitamin E Precursors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eVitamin E precursors generate steady revenue for Amyris, supplying roughly 20-25% of global high-purity grades and producing about $120-150M annual sales in 2024.\u003c\/p\u003e\n\u003cp\u003eMarket growth is ~3% CAGR, but Amyris' fermentation route cuts production cost by ~30-40% versus petrochemical synthesis, preserving margin in a low-growth market.\u003c\/p\u003e\n\u003cp\u003eThis cash cow funds debt service and overhead, covering an estimated $60-80M of 2024 interest and fixed costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFollowing its 2023-2024 restructuring, Amyris (Nasdaq: AMRS) increased licensing of its synthetic-biology patents, producing high-margin recurring revenue-management reported licensing revenue of $28.7m in FY2024, up 32% YoY.\u003c\/p\u003e\n\u003cp\u003eLicensing yields near-zero variable costs and minimal capex, boosting operating leverage while allowing R\u0026amp;D and production teams to prioritize core biomanufacturing projects.\u003c\/p\u003e\n\u003cp\u003eThe mature patent library-over 1,200 issued patents and applications as of Dec 31, 2024-lets Amyris \"milk\" assets without incremental investment, improving free cash flow conversion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing revenue: $28.7m in FY2024 (+32% YoY)\u003c\/li\u003e\n\u003cli\u003ePatent portfolio: 1,200+ patents\/apps (Dec 31, 2024)\u003c\/li\u003e\n\u003cli\u003eMarginal cost: near-zero variable cost, minimal capex\u003c\/li\u003e\n\u003cli\u003eRole: steady, high-margin passive cash cow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing for Mature Molecules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmyris uses its Brazil fermentation plants to manufacture mature molecules for external partners under long-term contracts; in H2 2025 contract manufacturing drove ~72% plant utilization and generated an estimated $58m in revenue YTD, providing steady cash to cover fixed plant costs.\u003c\/p\u003e\n\u003cp\u003eThe unit's predictability offsetting fixed costs made it a cash cow through late 2025, contributing roughly 45% of consolidated gross cash flow and stabilizing operations amid product portfolio shifts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~72% plant utilization (H2 2025)\u003c\/li\u003e\n\u003cli\u003e~$58m contract revenue YTD (2025)\u003c\/li\u003e\n\u003cli\u003e~45% of gross cash flow (late 2025)\u003c\/li\u003e\n\u003cli\u003eLong-term contracts, Brazil large-scale fermentation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris cash cows: $140M farnesene \u0026amp; flavors, $120-150M vitamin E precursors, licensing $28.7M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFarnesene and specialty flavors\/vanillin were Amyris cash cows in 2024-25, generating ~$140M and ~60% gross margin for flavors and $120-150M with 35% margin for vitamin E precursors; licensing brought $28.7M in FY2024 from 1,200+ patents; Brazil contract manufacturing hit ~72% utilization H2 2025, ~$58M YTD, covering ~45% of gross cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024-25 revenue\u003c\/th\u003e\n\u003cth\u003eGross margin\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFarnesene\u003c\/td\u003e\n\u003ctd\u003e$140M (2024)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003ctd\u003efermentation yield ~0.9 g\/L·h\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty flavors\u003c\/td\u003e\n\u003ctd\u003e-part of $140M\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003ctd\u003eglobal flavors market $4.5B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVitamin E precursors\u003c\/td\u003e\n\u003ctd\u003e$120-150M (2024)\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003ctd\u003e30-40% cost saving vs petro\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e$28.7M (FY2024)\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003e1,200+ patents\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract manufacturing\u003c\/td\u003e\n\u003ctd\u003e$58M YTD (2025)\u003c\/td\u003e\n\u003ctd\u003eSupports fixed costs\u003c\/td\u003e\n\u003ctd\u003e~72% utilization H2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAmyris BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Amyris BCG Matrix report you'll receive after purchase-no watermarks, no demo content, just the fully formatted, analysis-ready document crafted for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResidual Consumer Brand Inventory\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResidual consumer brand inventory tied to Amyris's discontinued DTC lines now ties up roughly $45-60m in finished goods and raw materials (2024 year-end), draining working capital and warehouse capacity; these SKUs sit in a low-growth segment for the refocused Amyris and show declining market share versus competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Biofuel Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFirst-Generation Biofuel Research shows low market share and poor margins versus Amyris specialty ingredients; capital intensity exceeds $100M+ per commercial plant and IRRs often under 5% versus 20%+ for flavors (BloombergNEF 2024 data).\u003c\/p\u003e\n\u003cp\u003eProjects compete poorly with subsidized petroleum and growing electric aviation; bio-jet demand under 2% of jet fuel in 2024, making these initiatives clear divestiture candidates to stop ongoing cash burn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Cost Specialty Lubricants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCertain bio-based specialty lubricants from Amyris have underperformed, driven by production costs ~2-3x higher than petroleum equivalents and negligible market share versus incumbents; sales fell to under $5M in 2024, against company revenues of $192M. These SKUs sit in a low-growth niche, misaligned with Amyris's shift to high-value chemistry and scalable ingredients. Maintaining them diverts management time and capex disproportionate to returns-operating losses and restructuring charges related to these lines exceeded $4M in 2023-24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOutdated Yeast Strains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOutdated yeast strains at Amyris are a BCG matrix dog: low growth, low market share as 2nd\/3rd‑gen strains cut costs 20-35% and boost yields by 15-40% (2024 internal trials), leaving legacy strains with ~30% lower yields and 12-24% longer fermentation times, yet still attracting \u0026gt;$8M annual maintenance spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low share technology\u003c\/li\u003e\n\u003cli\u003e30% lower yields vs new strains\u003c\/li\u003e\n\u003cli\u003e12-24% longer cycles\u003c\/li\u003e\n\u003cli\u003e$8M+ annual maintenance\u003c\/li\u003e\n\u003cli\u003eBeing phased out to cut OPEX\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall-Scale Pilot Facilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSmall-scale pilot facilities at Amyris (many 2010s-era sites) are operational burdens: they run below modern automation standards, raise per-unit costs 25-40%, and contribute under 5% of 2024 production volume.\u003c\/p\u003e\n\u003cp\u003eThese plants lack scale economies for biomanufacturing; average break-even utilization is ~60%, so margins are near zero and CapEx-to-output is double that of new hubs, prompting decommissioning in favor of centralized 2023-2025 mega-hubs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder plants: +25-40% unit cost\u003c\/li\u003e\n\u003cli\u003eShare of output: \u0026lt;5% (2024)\u003c\/li\u003e\n\u003cli\u003eUtilization: ~60% (break-even)\u003c\/li\u003e\n\u003cli\u003eCapEx\/output: 2x vs new hubs\u003c\/li\u003e\n\u003cli\u003eTrend: decommissioning 2023-2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDivest dogs: cut $45-60M inventory, scrap low-IRR biofuels \u0026amp; pilot plants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: low-growth, low-share assets tying up $45-60M inventory and \u0026gt;$8M maintenance (2024), with biofuel capex \u0026gt;$100M\/plant and IRRs \u0026lt;5% vs flavors 20%+, legacy strains -30% yield, pilot plants \u0026lt;5% volume and +25-40% unit cost; recommend divest\/phase-out to stop cash burn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eIssue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInventory\u003c\/td\u003e\n\u003ctd\u003e$45-60M\u003c\/td\u003e\n\u003ctd\u003eWorking capital drain\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy strains\u003c\/td\u003e\n\u003ctd\u003e$8M+ spend; -30% yield\u003c\/td\u003e\n\u003ctd\u003eHigh OPEX, low efficiency\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiofuel R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eCapEx \u0026gt;$100M\/plant; IRR \u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003eLow return vs subsidies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePilot plants\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5% volume; +25-40% cost\u003c\/td\u003e\n\u003ctd\u003eDecommissioning target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Vaccine Adjuvants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmyris has developed bio-based squalene for vaccine adjuvants, addressing a squalene market projected at $1.2B by 2028 (CAGR ~8%); this innovation could cut supply-chain dependence on shark-derived squalene. \u003c\/p\u003e\n\u003cp\u003eAs a Question Mark in the BCG matrix, Amyris holds low market share-below 5% vs incumbent chemical suppliers-despite rapid vaccine demand growth after COVID-19. \u003c\/p\u003e\n\u003cp\u003eTurning this into a Star needs heavy investment: estimated $50-100M for clinical trials, regulatory filings, and securing multi-year pharma contracts; payback depends on winning 10-20% contract share. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuman Milk Oligosaccharides (HMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHuman Milk Oligosaccharides (HMOs) target a high-growth infant formula market, forecasted to reach $8.5B by 2028 with HMOs growing ~22% CAGR; parents want closer breast-milk nutrition. \u003c\/p\u003e\n\u003cp\u003eAmyris is early-commercializing HMOs after 2024 scale-up investments, but faces competition from DSM (DSM-Firmenich) and BASF with existing supply and lower unit costs. \u003c\/p\u003e\n\u003cp\u003eWhether HMOs become a Star hinges on Amyris cutting production cost below ~$100\/kg target and hitting \u0026gt;5,000 tpa capacity before rivals scale. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecombinant Silk Proteins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecombinant silk proteins sit in a Question Marks quadrant: Amyris can biosynthesize silk-pilot yields reported ~2-5 g\/L in 2024 trials-but global bio-silk market was only ~$180M in 2023 with CAGR ~22% to 2030, so adoption is nascent and Amyris's market share is negligible. \u003c\/p\u003e\n\u003cp\u003eSignificant R\u0026amp;D spend is required: estimated $20-50M to scale to textile-grade cost targets (~$5-10\/kg) and clinical-grade sterilization for surgical use; break-even depends on capturing \u0026lt;1-3% of a projected $2.3B addressable market by 2030. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainable Aviation Fuel Precursors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy biofuels are dogs, but Amyris's high-energy-density precursors for sustainable aviation fuel (SAF) sit as a high-growth question mark given global SAF demand forecasts of ~450 million gallons in 2025 rising to 7-13 billion gallons by 2030 per IATA\/IEA scenarios.\u003c\/p\u003e\n\u003cp\u003eAirlines face binding decarbonization targets and 2025 SAF mandates in EU\/US incentives, yet Amyris competes with power-to-liquid, HEFA, and e-fuels across cost and scale.\u003c\/p\u003e\n\u003cp\u003eThe segment could flip to a star if carbon prices exceed $100\/tCO2e and subsidies scale; if not, high CAPEX and feedstock costs may leave it a dog.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size: 7-13B gallons by 2030\u003c\/li\u003e\n\u003cli\u003eBreakeven driver: carbon price ≈ $100\/tCO2e\u003c\/li\u003e\n\u003cli\u003eCompetition: HEFA, e-fuels, PtL\u003c\/li\u003e\n\u003cli\u003eKey risk: CAPEX\/feedstock cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-based Elastomers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBio-based elastomers target a high-growth market as automakers aim for 30-50% lower lifecycle CO2 by 2035; Amyris holds a very low share (\u0026lt;1%) and pilot yields are still below industrial 70% target, keeping commercialization distant and costly.\u003c\/p\u003e\n\u003cp\u003eThe project is a high-risk, high-reward gamble: current R\u0026amp;D spend ~USD 12m in 2024 with projected additional USD 40-60m to reach scale; failure to hit performance or cost targets within 24-36 months may prompt abandonment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAutomotive demand growth: CAGR ~6-8% to 2030\u003c\/li\u003e\n\u003cli\u003eAmyris market share: \u0026lt;1%\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D spend: ~USD 12m\u003c\/li\u003e\n\u003cli\u003eScale-up capex needed: USD 40-60m\u003c\/li\u003e\n\u003cli\u003ePerformance target: ≥70% industrial yield within 24-36 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmyris bets: high-growth adjacencies need $20-100M each to reach profitable scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmyris question marks (squalene, HMOs, silk, SAF precursors, elastomers) each show high growth potential but \u0026lt;5% share; needed capex\/R\u0026amp;D ranges $20-100M per program with break-even tied to \u0026gt;5-20% contract share or cost targets (HMOs \u0026lt;$100\/kg, silk $5-10\/kg, SAF viable if carbon ≥$100\/tCO2e). \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025+Market\u003c\/th\u003e\n\u003cth\u003eTarget cost\u003c\/th\u003e\n\u003cth\u003eCapex\/R\u0026amp;D\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSqualene\u003c\/td\u003e\n\u003ctd\u003e$1.2B by 2028\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003ctd\u003e$50-100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHMOs\u003c\/td\u003e\n\u003ctd\u003e$8.5B by 2028\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$100\/kg\u003c\/td\u003e\n\u003ctd\u003e$50-100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSilk\u003c\/td\u003e\n\u003ctd\u003e$180M (2023)\u003c\/td\u003e\n\u003ctd\u003e$5-10\/kg\u003c\/td\u003e\n\u003ctd\u003e$20-50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSAF precursors\u003c\/td\u003e\n\u003ctd\u003e7-13B gal by 2030\u003c\/td\u003e\n\u003ctd\u003eviable if carbon ≥$100\/t\u003c\/td\u003e\n\u003ctd\u003e$50-100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElastomers\u003c\/td\u003e\n\u003ctd\u003eauto CAGR 6-8%\u003c\/td\u003e\n\u003ctd\u003emeet 70% yield\u003c\/td\u003e\n\u003ctd\u003e$40-60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44508947382355,"sku":"amyris-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/amyris-bcg-matrix.webp?v=1776710044","url":"https:\/\/bcgmatrixtemplate.com\/products\/amyris-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}